



*HS*

**Express Mail No.: EL 500 577 335 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Bennett et al.

Confirmation No.: 6892

Application No.: 09/642,557

Group Art Unit: 1626

Filed: August 18, 2000

Examiner: S. Wright

For: PYRAZOLOANTHRONE AND  
DERIVATIVES THEREOF AS JNK  
INHIBITORS AND  
COMPOSITIONS AND METHODS  
RELATED THERETO

Attorney Docket No.: 10624-046-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **BV-CC** which are listed on the accompanying form PTO-1449 entitled "List of References Cited By Applicant." Copies of references **BV-CC** are submitted herewith. Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Reference **CC** submitted herein is a hard-copy of a page from Calbiochem<sup>®</sup>'s website ([http://www.calbiochem.com/Products/ProductDetail\\_CBCB.asp?catNO=420119](http://www.calbiochem.com/Products/ProductDetail_CBCB.asp?catNO=420119)). The page was printed on December 18, 2002. Reference **CC** is not prior art against the subject application.

Applicants request that the Examiner review all the references identified on the attached form PTO-1449, and that they be made of record in the file history of the above-captioned application.

Pursuant to 37 C.F.R. § 1.97(c), this Supplemental Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits, but before the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution on the application. Accordingly, Applicants authorize payment of the required fee as set forth in §1.17(p). This fee is estimated to be \$180.00.

In the event that the Patent Office believes that any additional fee is due, please charge the fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Date December 18, 2002

Respectfully submitted,

*By: Anthony M. Insogna, Reg. No. 35,205*  
*Anthony M. Insogna, Reg. No. 36,343*  
*35,203*

Anthony M. Insogna

(Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090